Clinical Study on the Safety and Efficacy of Allogeneic, Umbilical Cord Blood Derived CAR T-cell Therapy for Refractory Systemic Lupus Erythematosus
Chengdu Ucello Biotechnology Co., Ltd. is developing an allogeneic CAR-T cell therapy derived from umbilical cord blood for the treatment of refractory systemic lupus erythematosus (SLE). This therapy addresses a significant unmet medical need in a patient population that has failed conventional treatments. The market for SLE therapies is growing, with increasing awareness and diagnosis rates. The competitive landscape includes traditional immunosuppressants and emerging biologics, but the unique mechanism of action and potential for durable remission offered by CAR-T therapies may provide a competitive edge. Diligence should focus on regulatory pathways, potential partnerships for manufacturing and distribution, and the evolving landscape of CAR-T therapies in autoimmune diseases.
Indication: SLE - Systemic Lupus Erythematosus
Modality: cell therapy
Target: Chimeric Antigen Receptor T-cells (CAR-T) targeting CD19 and BCMA
Sponsor: Chengdu Ucello Biotechnology Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Dec 10, 2025
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Chimeric Antigen Receptor T-cells (CAR-T) targeting CD19 and BCMA
View original source fields
Condition raw: SLE - Systemic Lupus Erythematosus
Condition normalized: SLE - Systemic Lupus Erythematosus
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Chimeric Antigen Receptor T-cells (CAR-T) targeting CD19 and BCMA
Target normalized: Chimeric Antigen Receptor T-cells (CAR-T) targeting CD19 and BCMA